342: FDA cuts, zombie biotechs, and too much weight loss?
The Readout Loud
Optimism in Gene Therapy Development
This chapter explores the hopeful outlook of pharmaceutical leaders regarding the Trump administration amidst industry cuts, and highlights Solid Biosciences' promising advancements in gene therapy for Duchenne muscular dystrophy. It reflects on the company's resilience through past challenges while navigating a competitive landscape for effective treatment options.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
